A pancreas tumor derived organoid study: from drug screen to precision medicine

Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Jia, Yang, Man, Atteh, Lawrence, Liu, Pinyan, Mao, Yongcui, Meng, Wenbo, Li, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314636/
https://www.ncbi.nlm.nih.gov/pubmed/34315500
http://dx.doi.org/10.1186/s12935-021-02044-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314636/
https://www.ncbi.nlm.nih.gov/pubmed/34315500
http://dx.doi.org/10.1186/s12935-021-02044-1

Ejemplares similares